期刊
CELL
卷 173, 期 5, 页码 1135-+出版社
CELL PRESS
DOI: 10.1016/j.cell.2018.04.013
关键词
-
资金
- NIH [DK057978, HL088093, HL105278, ES010337]
- NIEHS [P42ES010337]
- Glenn Foundation for Medical Research
- Leona M. and Harry B. Helmsley Charitable Trust [2017PG-MED001]
- Ipsen/Biomeasure
- California Institute for Regenerative Medicine [RB5-07394]
- Ellison Medical Foundation
- Salk Cores
A primary cause of disease progression in type 2 diabetes (T2D) is beta cell dysfunction due to inflammatory stress and insulin resistance. However, preventing beta cell exhaustion under diabetic conditions is a major therapeutic challenge. Here, we identify the vitamin D receptor (VDR) as a key modulator of inflammation and beta cell survival. Alternative recognition of an acetylated lysine in VDR by bromodomain proteins BRD7 and BRD9 directs association to PBAF and BAF chromatin remodeling complexes, respectively. Mechanistically, ligand promotes VDR association with PBAF to effect genome-wide changes in chromatin accessibility and enhancer landscape, resulting in an anti-inflammatory response. Importantly, pharmacological inhibition of BRD9 promotes PBAF-VDR association to restore beta cell function and ameliorate hyperglycemia in murine T2D models. These studies reveal an unrecognized VDR-dependent transcriptional program underpinning beta cell survival and identifies the VDR:PBAF/BAF association as a potential therapeutic target for T2D.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据